Quick Answer
Denali Therapeutics Inc. reported Stockholders Equity of $1.01 billion for fiscal year 2025.
Denali Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $1.01B | -17.6% |
| 2024 | $1.23B | +19.3% |
| 2023 | $1.03B | -1.1% |
| 2022 | $1.04B | +8.3% |
| 2021 | $962.29M | -16.4% |
| 2020 | $1.15B | +191.4% |
| 2019 | $394.89M | -27.8% |
| 2018 | $546.85M | +17.4% |
| 2017 | $465.80M | +594.7% |
| 2016 | -$94.15M | -502.2% |
| 2015 | -$15.63M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $926.20M | -29.8% | -9.8% |
| June 30, 2025 | $1.03B | -26.0% | -8.5% |
| March 31, 2025 | $1.12B | -22.9% | -8.7% |
| December 31, 2024 | $1.23B | +19.3% | -6.7% |
| September 30, 2024 | $1.32B | +17.9% | -4.9% |
| June 30, 2024 | $1.39B | +16.9% | -4.7% |
| March 31, 2024 | $1.46B | +50.6% | +41.2% |
| December 31, 2023 | $1.03B | -1.1% | -7.8% |
- Denali Therapeutics Inc. showed a decrease of -17.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2015–2025 period, Denali Therapeutics Inc.’s stockholders equity has grown by 6584.3% (from -$15.63 million to $1.01 billion).
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: